BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36229873)

  • 1. Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma.
    Hölting TLB; Cidre-Aranaz F; Matzek D; Popper B; Jacobi SJ; Funk CM; Geyer FH; Li J; Piseddu I; Cadilha BL; Ledderose S; Zwilling J; Ohmura S; Anz D; Künkele A; Klauschen F; Grünewald TGP; Knott MML
    Mol Cancer; 2022 Oct; 21(1):199. PubMed ID: 36229873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
    Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
    Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
    Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
    Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
    Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.
    Knott MML; Hölting TLB; Ohmura S; Kirchner T; Cidre-Aranaz F; Grünewald TGP
    Cancer Metastasis Rev; 2019 Dec; 38(4):625-642. PubMed ID: 31970591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
    Grohar PJ; Kim S; Rangel Rivera GO; Sen N; Haddock S; Harlow ML; Maloney NK; Zhu J; O'Neill M; Jones TL; Huppi K; Grandin M; Gehlhaus K; Klumpp-Thomas CA; Buehler E; Helman LJ; Martin SE; Caplen NJ
    Cell Rep; 2016 Jan; 14(3):598-610. PubMed ID: 26776507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex.
    Mo J; Tan K; Dong Y; Lu W; Liu F; Mei Y; Huang H; Zhao K; Lv Z; Ye Y; Tang Y
    Oncogene; 2023 Jan; 42(1):11-25. PubMed ID: 36357572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization.
    Pedot G; Marques JG; Ambühl PP; Wachtel M; Kasper S; Ngo QA; Niggli FK; Schäfer BW
    Neoplasia; 2022 May; 27():100784. PubMed ID: 35366465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.
    Yasir M; Park J; Chun W
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1.
    Deng Q; Natesan R; Cidre-Aranaz F; Arif S; Liu Y; Rasool RU; Wang P; Mitchell-Velasquez E; Das CK; Vinca E; Cramer Z; Grohar PJ; Chou M; Kumar-Sinha C; Weber K; Eisinger-Mathason TSK; Grillet N; Grünewald TGP; Asangani IA
    Cell Rep; 2022 Jun; 39(11):110971. PubMed ID: 35705030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.
    Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ
    Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Druggable Rheostat for Ewing Sarcoma?
    Weiss KR; Bailey KM
    Clin Cancer Res; 2022 Oct; 28(20):4360-4362. PubMed ID: 35921177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
    Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
    Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
    Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
    Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
    Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
    J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.